|
TSC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.48860043683408E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.25429999719984E-09 |
| Normal-vs-Stage2 |
1.70660000020639E-07 |
| Normal-vs-Stage3 |
2.90319990270405E-11 |
| Normal-vs-Stage4 |
2.06579999773027E-08 |
| Stage1-vs-Stage2 |
9.899000E-01 |
| Stage1-vs-Stage3 |
5.936100E-02 |
| Stage1-vs-Stage4 |
3.423000E-01 |
| Stage2-vs-Stage3 |
2.077800E-01 |
| Stage2-vs-Stage4 |
4.987400E-01 |
| Stage3-vs-Stage4 |
7.056600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.63109978249076E-10 |
| Normal-vs-AfricanAmerican |
1.787010E-04 |
| Normal-vs-Asian |
5.99810000001533E-07 |
| Caucasian-vs-AfricanAmerican |
5.107200E-01 |
| Caucasian-vs-Asian |
7.600000E-02 |
| AfricanAmerican-vs-Asian |
7.209600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.82740045318042E-10 |
| Normal-vs-Female |
1.58259960691964E-10 |
| Male-vs-Female |
4.165200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.10680003945407E-09 |
| Normal-vs-Age(41-60Yrs) |
3.81920051140128E-10 |
| Normal-vs-Age(61-80Yrs) |
7.5777051300463E-11 |
| Normal-vs-Age(81-100Yrs) |
3.85219999999853E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.024400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.946200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.553700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.668200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.661800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.149420E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.989740E-04 |
| Classical-VS-Follicular |
7.605400E-01 |
| Classical-VS-Other |
5.506800E-01 |
| Classical-VS-Normal |
5.12109998851429E-09 |
| Tall-VS-Follicular |
3.918500E-03 |
| Tall-VS-Other |
2.692200E-01 |
| Tall-VS-Normal |
1.16862075572044E-12 |
| Follicular-VS-Other |
6.637400E-01 |
| Follicular-VS-Normal |
2.22999996246642E-09 |
| Other-VS-Normal |
3.777800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.96430024760275E-10 |
| Normal-vs-N1 |
2.82300000042923E-07 |
| N0-vs-N1 |
8.928400E-01 |
|
|
